GlassScriptPhysician profile
Richard E Mccullough
NPI 1336143619
$3,765.61
in general payments reported to CMS, 2019-2025
31 companies · $559 in 2025
The $559 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $321 · 2021: $514 · 2022: $418 · 2023: $489 · 2024: $460 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $687.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $620.58 | 2019-2024 | Xarelto |
| Abbvie INC. | $367.49 | 2021-2025 | |
| Pfizer INC. | $284.88 | 2019-2025 | |
| Astellas Pharma US INC | $268.47 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $215.38 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $213.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $195.36 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $104.12 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $101.40 | 2019-2025 | Evenity, Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $84.39 | 2019-2022 | |
| Ardelyx, INC. | $66.97 | 2024-2025 | Ibsrela |
| Melinta Therapeutics, LLC | $63.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $58.81 | 2021 | |
| Merck Sharp & Dohme LLC | $58.27 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $45.04 | 2022-2024 | Dexcom G6 Transmitter |
| Inari Medical, INC. | $42.48 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $37.42 | 2023-2024 | Rexulti |
| Shield Therapeutics INC | $37.36 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $31.30 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ethicon US, LLC | $27.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.98 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $20.10 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.89 | 2025 | Lifevest |
| Valeritas, INC. | $16.28 | 2019 | |
| Radius Health, INC. | $14.30 | 2019 | |
| Medtronic Minimed, INC. | $13.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.74 | 2019 | |
| Allergan, INC. | $12.43 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.00 | 2021 | |
| Phathom Pharmaceuticals, INC. | $8.17 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mccullough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.